Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 28;14:17588359221109196. doi: 10.1177/17588359221109196

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — (a) OS in patients with an increase in galectin-1 levels on day 15 compared to day 1 (ratio >1.0; n = 24) versus a decrease (ratio < 1.0; n = 21) measured with ELISA. (b) A heatmap of a gene panel from previously established regorafenib targets on baseline (day 1, n = 21) compared to on-treatment (day 15, n = 13) using RNA sequencing. (c) Normalized enrichment score of established hallmark pathways (MSigDB, 2019) on-treatment (day 15, n = 13) compared to baseline (day 1, n = 21) according to Gene Set Enrichment Analysis in patients with a short survival and long survival. (d) OS in patients with a gain (n = 12) of chromosome 19q13.12-q13.2 versus no gain (n = 22). (e) Validation of chromosome 19q13.12-q13.2 in RNA sequencing dataset in patients with a gain (n = 12) versus no gain (n = 22) compared to a random region on chromosome 19p13.2-13.13.

ELISA, enzyme-linked immunosorbent assay; OS, overall survival.